Predict your next investment

HEALTHCARE | Biotechnology
rhinocyte.com

See what CB Insights has to offer

Founded Year

2005

Stage

Convertible Note | Alive

Total Raised

$4.69M

Last Raised

$250K | 6 yrs ago

About RhinoCyte

RhinoCyte is a biotechnology company that has developed a method of isolating adult stem cells located in the olfactory regions of the mucosal lining of the human nasal passageway, which can be used in therapies for spinal cord injury, multiple sclerosis, ALS and Parkinson's Disease.

RhinoCyte Headquarter Location

1044 E. Chestnut Street

Louisville, Kentucky, 40204,

United States

502-410-4512

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing RhinoCyte

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

RhinoCyte is included in 2 Expert Collections, including Regenerative Medicine.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharma Tech

5,238 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.